Innoxel Lifesciences, Bharat Parenterals' subsidiary, begins U.S. commercial supply with its first CMO product
Bharat Parenterals' subsidiary Innoxel Lifesciences has commenced commercial supply to the United States, launching its first CMO product, made at Vadodara, in the U.S. market on October 20, 2026.
By ScoutQuest · · 1 min read
- U.S. launch date
- launched the product in the U.S. market on October 20, 2026
- FY26 deal count
- Innoxel signed 23 deals in FY26, seven out-licensing and sixteen CMO/CDO
- Total deals since inception / active partners
- total since inception to 48, and it works with 19 active partners
- Release
- Launch / capacity
_Business-line figures_
🔬 Innoxel's sponsor partner, whose identity and product details the company is not disclosing under confidentiality obligations, launched the product in the U.S. market on October 20, 2026; Auxilla Pharmaceuticals and Research LLP served as the development partner and the sponsor selected Innoxel as its manufacturing partner.
🔬 The launch changes the make-up of Innoxel's revenue: its FY26 revenue was entirely from licensing, split between upfront and milestone payments, and commercial supply adds a recurring line the company says is earned on every batch shipped to partners selling in the U.S.
📌 Innoxel signed 23 deals in FY26, seven out-licensing and sixteen CMO/CDO, taking its total since inception to 48, and it works with 19 active partners across the United States, the European Union and India.
🔬 Bharat Parenterals says the U.S. launch is the first of the two CMO products it expects to commercialise in FY27, and Chairman and Managing Director Bharat Desai says more CMO launches are lined up over the next two quarters and into next year.
Also from Bharat Parenterals
Shareholders approve preferential share issue and higher Section 186(2) limits
24 Oct 2026
Bharat Parenterals schedules Q2 & H1FY27 earnings conference call for October 30, 2026
24 Oct 2026
Board meeting on October 29 to consider and approve September quarter and half year results
24 Oct 2026
More numbers
- Innoxel revenue, FY26₹72.4 crore
- Innoxel milestone-linked licensing revenue, FY26₹55.3 crore
- Innoxel upfront licensing revenue, FY26₹17.1 crore
- Deals signed by Innoxel, FY2623
- Total deals signed by Innoxel since inception48
- Active partners of Innoxel19
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.